These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22300857)

  • 1. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine.
    Di Mario S; Basevi V; Borsari S; Balduzzi S; Magrini N
    Lancet Oncol; 2012 Feb; 13(2):e50; author reply e50. PubMed ID: 22300857
    [No Abstract]   [Full Text] [Related]  

  • 2. Success of HPV vaccination is now a matter of coverage.
    Schiffman M; Wacholder S
    Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169
    [No Abstract]   [Full Text] [Related]  

  • 3. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
    Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
    Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.
    Sow PS; Watson-Jones D; Kiviat N; Changalucha J; Mbaye KD; Brown J; Bousso K; Kavishe B; Andreasen A; Toure M; Kapiga S; Mayaud P; Hayes R; Lebacq M; Herazeh M; Thomas F; Descamps D
    J Infect Dis; 2013 Jun; 207(11):1753-63. PubMed ID: 23242542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynaecological cancer: HPV vaccine: is age just a number?
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
    Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
    Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K; Romanowski B
    BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
    Kreimer AR; González P; Katki HA; Porras C; Schiffman M; Rodriguez AC; Solomon D; Jiménez S; Schiller JT; Lowy DR; van Doorn LJ; Struijk L; Quint W; Chen S; Wacholder S; Hildesheim A; Herrero R;
    Lancet Oncol; 2011 Sep; 12(9):862-70. PubMed ID: 21865087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
    Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
    Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
    J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.
    Zhu F; Li J; Hu Y; Zhang X; Yang X; Zhao H; Wang J; Yang J; Xia G; Dai Q; Tang H; Suryakiran P; Datta SK; Descamps D; Bi D; Struyf F
    Hum Vaccin Immunother; 2014; 10(7):1795-806. PubMed ID: 25424785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical cancer vaccination: the real meaning of cross-protection and its impact on the prevention.
    De Carvalho NS
    Vaccine; 2008 Nov; 26(50):6293-4. PubMed ID: 18804508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
    J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.